Adial Pharmaceuticals, Inc. (ADIL)
- Previous Close
1.0200 - Open
1.0100 - Bid 0.9828 x 100
- Ask 1.0600 x 200
- Day's Range
0.9925 - 1.0300 - 52 Week Range
0.7700 - 4.3000 - Volume
44,788 - Avg. Volume
2,820,280 - Market Cap (intraday)
6.467M - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9900 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.50
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
www.adialpharma.comRecent News: ADIL
View MorePerformance Overview: ADIL
Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADIL
View MoreValuation Measures
Market Cap
6.47M
Enterprise Value
4.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.51
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-104.18%
Return on Equity (ttm)
-320.96%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-12.19M
Diluted EPS (ttm)
-3.9900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.99M